Related Experiment Video
Updated: Jun 17, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Gene therapy in metachromatic leukodystrophy
C Sevin1, N Cartier-Lacave, P Aubourg
1French Institute for Health and Medical Research, Paris Descartes University and Department of Pediatric Neurology, Hôpital Saint-Vincent de Paul, Paris, France.
Abstract:
Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by deficiency of the lysosomal enzyme arylsulfatase A. Deficiency of this enzyme results in intralysosomal storage of sphingolipid cerebroside 3-sulfates (sulfatides), which are abundant in myelin and neurons. A pathological hallmark of MLD is demyelination and neurodegeneration, causing various and ultimately lethal neurological symptoms. This review discusses the potential therapeutic application of hematopoietic stem cell gene therapy and intracerebral gene transfer (brain gene therapy) in patients with MLD.
Related Concept Videos
Gene Therapy
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Satellite Stem Cells and Muscular Dystrophy

